Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine

European Journal of Clinical Pharmacology

Volumn 54, Issue 7, 1998, Pages 561-565

  Isohanni, M H ^a   Neuvonen, P J ^a   Palkama, V J ^a   Olkkola, K T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Erythromycin; Interaction; Lignocaine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEETHYLLIDOCAINE; ERYTHROMYCIN; ITRACONAZOLE; LIDOCAINE; LIDOKAINKLORID; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LOCAL ANESTHESIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; ERYTHROMYCIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; LIDOCAINE; MALE; MIXED FUNCTION OXYGENASES;

EID: 0031793525     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050513     Document Type: Article

References (32)

1. Al-Asady SA, Black GL, Lennard MS, Tucker GT, Woods HF (1989) Inhibition of lignocaine metabolism by beta-adrenoceptor antagonists in rat and human liver microsomes. Xeno-biotica 19: 929-944
2. Allenmark S, Edebo A, Lindgren K (1990) Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 532: 203-206
3. Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32: 624-626
4. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA (1989) Lignocaine metabolism in human liver microsomes by P450IIIA4. Clin Pharmacol Ther 46: 521-527
5. Bax NDS, Tucker GT, Lennard MS, Woods HF (1985) The impairment of lignocaine clearance by propranolol - major contribution from enzyme inhibition. Br J Clin Pharmacol 19: 597-603
6. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32: 210-258
7. Burney RG, Difazio CA, Peach MJ, Petrie KA, Silvester MJ (1974) Antiarrhythmic effects of lidocaine metabolites. Am Heart J 88: 765-769
8. Demedts P, Wauters A, Franck F, Neels H (1996) Simultaneous determination of lidocaine, bupivacaine and their two main metabolites using gas chromatography and a nitrogen-phosporus detector: selection of stationary phase and chromatographiC conditions. Ther Drug Monit 18: 208-211
9. Feely J, Wilkinson GR, McAllisler CB, Wood JJ (1982) Increased toxicity and reduced clearance of lignocaine by cimetidine. Ann Intern Med 96: 592-594
10. Gascon M-P. Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41: 573-578
11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
12. Imaoka S, Enomoto K, Oda Y, Aada A, Fujimri M, Shimada T, Fujita S, Guengerich FP, Funae Y (1990) Lidocaine metabolism by human P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 255: 1385-1391
13. Jackson JE, Bentley JB, Glass SJ, Fukui T, Gandolfi AJ, Plachetka JR (1985) Effects of histamine-2 receptor blockade on lignocaine kinetics. Clin Pharmacol Ther 37: 544-548
14. Keenaghan JB, Boyes RN (1972) The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther 180: 454-463
15. Laakso S, Scheinin M, Anttila M (1990) Determination of erythromycin base and 2-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr 526: 474-486
16. Lorec A-M, Bruguerolle B, Attolini L, Roucoules X (1994) Rapid simultaneous determination of lidocaine, bupivacaine and their two main metabolites using capillary gas-liquid chromatography with nitrogen-phosporus detector. Ther Drug Monit 16: 592-595
17. Miners JO, Wing LMH, Lillywhite KJ, Smith KJ (1984) Failure of 'therapeutic' doses of β-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. Br J Clin Pharmacol 18: 853-860
18. Nelson SD, Garland WA, Trager WF (1974) Lack of evidence for the formation of N hydroxyamide metabolites of lidocaine in man. Res Commun Chem Pathol Pharmacol 8: 45-54
19. Noble DW, Bannister J, Lamont M, Andersson T, Scott DB (1994) The effect of oral omepraxole on the disposition of lignocaine. Anaesthesia 49: 497-500
20. Ochs HR, Carstens G, Greenblatt DJ (1980) Reduction in lidocaine clearance during continuous infusion and coadministration of propranolol. N Engl J Med 303: 373-377
21. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53: 298-305
22. Olkkola KT, Backman J, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 55: 481-485
23. Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82: 511-516
24. Robson RA, Wing MH, Miners JO, Lillywhite KJ, Birkett DJ (1985) The effect of ranitidine on the disposition of lignocaine. Br J Clin Pharmacol 20: 170-173
25. Rowland M, Tozer TN (1995) Elimination. In: Rowland M, Tozer TN (eds) Clinical pharmacokinetics: concepts and applications, 3rd edn. Williams Wilkins, Baltimore, pp 156-183
26. Rowland K, Yeo WW, Ellis SW, Chadwick IG, Haq L, Lennard MS, Jackson PR, Ramsay LE, Tucker GT (1994) Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy-propranolol. Br J Clin Pharmacol 38: 9-14
27. Suzuki T, Ishida R, Matsui S, Masubuchi Y, Narimatzu S (1993) Kinetic analysis of mutual metabolic inhibition of lignocaine and propranolol in rat liver microsomes. Biochem Pharmacol 45: 1528-1530
28. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M (1973) Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 78: 499-508
29. Tucker GT, Mather LE (1979) Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet 4: 241-278
30. Tucker GT, Bax NDS, Lennard MS, Al-Asady S, Bharaj HS, Woods HF (1984) Effects of β-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol 17: 21S-28S
31. Ujhelyi MR, O'Rangers EA, Fan C, Kluger J, Pharand C, Chow MSS (1993) The pharmacokinetic and pharmacodynamic interaction between propafenone and lignocaine. Clin Pharmacol Ther 53: 38-48
32. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56: 601-607